An observational study in Parkinson's Disease, sponsored by AbbVie. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Parkinson Disease by AbbVie — 5 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · AbbVie.
Among the 44 studies in Parkinson Disease by AbbVie, this one has the largest enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 39th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Croatia and 6 more countries
Ages 18–69
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in Spain
Ages 18+
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Germany
Ages 18–67
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,000 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 63 across the 25 interventional studies, 131 across the 18 observational. Of the 34 that completed or were terminated, 18 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
5 of the studies in Parkinson Disease by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07284342AbbVieA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa | 2027-01 |
| NCT05916157AbbVieAn Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | 2027-01 |
| NCT06639620AbbVieStudy To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting | 2027-03 |
| NCT06965374AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease | 2027-06 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Parkinson Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa.
Inclusion Criteria:
- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.
Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa.
Mean Base Infusion Rate
Mean base infusion rate (ml/hour) will be assessed
Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean Low Infusion Rate
Mean low infusion rate (ml/hour) will be assessed
Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean High Infusion Rate
Mean high infusion rate (ml/hour) will be assessed
Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Plan to share: Undecided
Ran from Apr 2025 to primary completion in Jul 2025, 3 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2025 → Jul 2025 and completion Dec 2025 → Jul 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.